CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 30 target
Drug / intervention
Neoantigen Polypeptide Vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06195293
NCT06195293Phase 1RecruitingOn TrackUpdated 24mo ago
CompareCT.gov

Anti-cancer Neoantigen Polypeptide Vaccine to Treat Advanced Solid Tumors: Phase I Clinical Trial

Second Affiliated Hospital of Guangzhou Medical University·interventional·Posted Jan 8, 2024·Updated Jun 26, 2024

In Brief

A Phase 1 clinical trial evaluating Neoantigen Polypeptide Vaccine for Solid Tumor, Adult. Currently recruiting, targeting 30 participants across 1 site.

Detailed Summary

The WES and RAN-seq will be performed to identify and verify neoantigens and appropriate polypeptide sequences will be verified, manufactured and protected for vaccine production by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the polypeptide vaccine for immunotherapy of human cancer patients. In this phase I study, the safety, tolerance, and preliminary efficacy of the polypeptide vaccine immunotherapy on human cancers will firstly be evaluated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Adult
CountriesChina
Collaborators--

Timeline

Phase 1Recruiting
202420252026202720282029203020312032203320342035203620372038
First PostedJan 8, 2024
Enrollment StartJun 4, 2024
Primary CompletionDec 30, 2029
Study CompletionDec 30, 2037
TodayJul 1, 2026
Enrollment to primary: 5.6 yearsPosted 2.5 years agoPrimary completion in 3.5 years

Interventions

Neoantigen Polypeptide Vaccinebiological

Deliver neoantigen polypeptide vaccine into patients for anti-ancer therapy.